Disclosed herein are methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, methods for treating a human subject by providing neuroprotection to the human subject, and methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient, comprising orally administering to the human patient or subject a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, for use in treating a human subject by providing neuroprotection to the human subject, or for use treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient.本發明揭示治療罹患多發性硬化症或呈現單一臨床症狀(clini-cally isolated syndrome)之人類患者的方法，藉由對人類個體提供神經保護來治療該人類個體之方法，及藉由在人類患者中增加證實疾病進展之時間、增加證實復發之時間或減少腦萎縮來治療罹患多發性硬化症或呈現單一臨床症狀之人類患者的方法，該等方法包含向該人類患者或個體經口投與約1.2 mg每日劑量之拉喹莫德(laquinimod)或其醫藥學上可接受之鹽。本發明亦提供一種具有約1.2 mg拉喹莫德或其醫藥學上可接受之鹽及醫藥學上可接受之載劑的醫藥口服單位劑型，其用於治療罹患多發性硬化症或呈現單一臨床症狀之人類患者，用於藉由對人類個體提供神經保護來治療該人類個體，或用於藉由在人類患者中增加證實疾病進展之時間、增加證實復發之時間或減少腦萎縮來治療罹患多發性硬化症或呈現單一臨床症狀之該人類患者。
